debt_leverage_profile
0.03x Total Debt / Equity (Conservative)
High
SEC-XBRL
interest_rate_sensitivity
Low direct sensitivity; Azenta carries minimal net debt (~$200M convertible notes) with ~$1.4B cash, so 200bps rate rise marginally improves net interest income
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Semiconductor fabrication components sourced from Taiwan (TSMC ecosystem) and rare-earth magnets/cryogenic parts concentrated in China
Inferred
Agent_Inference
international_expansion_readiness
Significant exposure: ~50% revenue from Europe (EUR/GBP) and Asia-Pacific (JPY/CNY); EUR and JPY depreciation vs USD compresses reported revenue materially
Inferred
Agent_Inference
geographic_footprint
Operations in US, Germany, UK, Japan, China, India; EUR (~25%), JPY (~10%), CNY (~8%) are top FX exposures; limited natural hedging in place
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
No single vendor exceeds 30% of input costs; cryogenic and robotic component supply is diversified, though specialized suppliers create moderate substitution friction
Inferred
Agent_Inference
business_model_type_primary
Life sciences services and sample management (B2B SaaS + equipment); cloud dependency is moderate—30-day termination would disrupt LIMS/informatics but core lab ops remain functional
Inferred
Agent_Inference
business_model_type_secondary
Genomics services (Genewiz/Azenta Life Sciences); cloud termination would impair data delivery pipelines within days but sequencing hardware operations continue independently
Inferred
Agent_Inference
switching_cost_profile
Moderate API coupling risk; proprietary LIMS and sample-tracking APIs create stickiness, but lack of dominant ecosystem lock-in limits extreme coupling risk
Inferred
Agent_Inference
howey_test_risk_index
Fails Howey Test; revenue derived from fee-for-service lab work and equipment sales—no investment contract, profit-sharing, or passive return mechanism present
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
High GDPR exposure due to genomic/biomedical data processed in EU/UK; CCPA applies to California-based clients; requires data localization and explicit consent frameworks
Inferred
Agent_Inference
antitrust_exposure_flag
Low-moderate; holds meaningful share in cold-chain sample storage and genomics sequencing services but faces competition from Thermo Fisher, ICON, and others—no dominant monopoly position
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Approximately 40-45% recurring (storage subscription, multi-year service contracts) vs 55-60% transactional (sequencing, synthesis per-order); recurring share growing post-portfolio repositioning
Inferred
Agent_Inference
monetization_vector
Hybrid: per-sample storage fees (recurring), per-project genomics services (transactional), and capital equipment sales with attached service contracts
Inferred
Agent_Inference
pricing_architecture
Cost-plus with market-rate benchmarking; genomics sequencing pricing faces deflationary pressure from Illumina/PacBio commoditization; storage pricing more stable with annual escalators
Inferred
Agent_Inference
pricing_power_rating
Moderate (6/10); sample storage has defensible pricing due to switching costs; sequencing/synthesis faces persistent price compression of ~10-15% annually industry-wide
Inferred
Agent_Inference
target_gross_margin_bracket
45.5% Gross Margin (Strong (40-60%))
High
SEC-XBRL
churn_vulnerability_index
Low free-rider risk; services are paid-per-use or subscription; no meaningful open-access tier that subsidizes non-paying users
Inferred
Agent_Inference
headcount_cost_structure
Moderately headcount-linear; lab services require skilled technicians, limiting pure sublinear scaling—doubling revenue likely requires ~70-80% headcount increase absent significant automation investment
Inferred
Agent_Inference
marginal_cost_of_growth
Moderate-high marginal cost; capacity expansion requires capex in freezer farms and sequencing instruments plus skilled labor; gross margins ~45-50% constrain leverage
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; Azenta does not operate a franchise model
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC efficiency likely improves via enterprise contract bundling, but lab capacity buildout capex intensifies; LTV/CAC ratio estimated 3-4x at current scale
Inferred
Agent_Inference
network_effect_present
Weak network effects; sample repository scale creates mild data aggregation value, but core services are not network-dependent—competitors can replicate without user-base disadvantage
Inferred
Agent_Inference
asset_efficiency_ratio
-0.3% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Tier 2 (moderate resilience); pharma/biotech R&D spending is relatively inelastic, but genomics project spend and capital equipment are discretionary and historically cut in downturns
Inferred
Agent_Inference
customer_segment_primary
Top segment: large pharmaceutical and biotechnology companies (est. 50-60% of revenue); top 10 customers likely represent 25-35% of revenue—moderate concentration risk
Inferred
Agent_Inference
customer_segment_secondary
Secondary segment: academic and government research institutions (~20-25% of revenue); grant-dependent spending creates cyclical vulnerability tied to NIH/government budget cycles
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
5.7% CapEx / Revenue (Moderate-CapEx)
High
SEC-XBRL
sec_cik
0000933974
High
SEC-EDGAR
ticker
AZTA
High
SEC-EDGAR